Neurolief

Focus: Neurolief is an Israeli biotech startup founded in 2023 specializing in digital neuromodulation therapy devices for neurological and psychiatric indications. The company is pre-revenue and very early stage with a focus on non-invasive nerve stimulation technology.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Neurolief

AI assessmentNot Hiring

No open roles listed right now. Follow Neurolief to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Relivion®

Migraine

N/A

Clinical Trials (1)

NCT05804396Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for Preventive Treatment of Migraine

N/A

Help build intelligence for Neurolief

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build groundfloor expertise in an emerging digital neuromodulation modality with multiple pipeline programs across migraine and depression indications
Early-stage company structure enables rapid skill development and direct exposure to leadership across R&D, regulatory, and commercial strategy
Expanding pipeline with 8 active clinical programs signals aggressive development trajectory and potential for multiple clinical catalysts

Watch Out For

Zero active job openings and undisclosed funding/employee count create uncertainty about hiring capacity and financial runway
Founded in 2023 with no revenue, limited clinical data transparency (all programs marked 'N/A' phase), and single-trial programs suggest very early clinical stage with high binary risk
Israeli location may limit visa sponsorship ease and talent pool access compared to US-based biotech hubs

Generated by Claude from Neurolief's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Relievion device- Treatment stimulation

Migraine

N/A

Clinical Trials (1)

NCT03398668Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine

N/A

External Combined Occipital and Trigeminal Nerve Stimulation

Depression

N/A

Clinical Trials (1)

NCT05178784EEG Biomarker Study for Participants in the Neurolief "MOOD" Trial

N/A

Relivion active

Acute Migraine

N/A

Clinical Trials (1)

NCT03631550The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine

N/A

OSTNS Neurostimulator

Headache, Migraine

N/A

Clinical Trials (1)

NCT02438553Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain

N/A

Neurolief system

Major Depressive Disorder

N/A

Clinical Trials (1)

NCT02805881Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)

N/A

Relievion Device- Treatment Stimulation

Migraine

N/A

Clinical Trials (1)

NCT03185559A Randomized, Double-blind Clinical Investigation to Evaluate the Use of the Relievion™ Device in Treating Migraine.

N/A

Relivion®DP- Active

MDD

N/A

Clinical Trials (1)

NCT04279522The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2023

Portfolio: 8 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

6 pipeline

Marketed

Pipeline